Clinical Study of Novel CAR-ITNK Cells Targeting CD70 and CLL1 for Refractory/Relapsed AML

NCT07336875 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

R/R AML

Interventions

BIOLOGICAL: CAR-ITNK Cells targeting CD70 and CLL1

Sponsor

Tongji Hospital